{"filings":[{"id":871156,"accession_number":"0001477932-26-003658","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-06-05T13:00:33+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab CEO urges Malaysia-China biotech co-development at May 21 forum","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Sam Tan spoke at the 2026 China-Malaysia Economic Cooperation Outlook Forum in Kuala Lumpur on May 21, 2026.","Tan called for moving biotechnology collaboration beyond trade into co-development, clinical validation, and commercialization.","Company highlighted its Fidelion Diagnostics Pte. Ltd. and VitaGuard MRD platform as a model for cross-border biotechnology structuring.","Proposed pillars include accelerated clinical validation for precision oncology, specialized diagnostics infrastructure, and AI-integrated healthcare under regional data rules.","No specific financial guidance, deal value, or other material quantitative changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107906,"accession_number":"0001477932-26-001379","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.","He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.","BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.","MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107905,"accession_number":"0001477932-26-000964","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab Corp. completes Chemrex governance restructuring; appoints Matthew Barsing as Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).","New officers expected in coming months; Chemrex remains wholly owned subsidiary under parent oversight.","July 2025 capital allocation framework approved for potential operational upgrades, subject to evaluation.","No definitive commitments on scope, timing, or scale of any initiative under evaluation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107904,"accession_number":"0001477932-26-000610","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.","Annual cancer incidence in region projected at 2.4M cases by 2030; company sees multi-billion-dollar market shift.","Fidelion Diagnostics Pte. Ltd. established as exclusive IP and commercialization vehicle outside Greater China.","Foundational steps completed by end 2025: global patent filings, recruitment, and regulatory prep with regional diagnostics partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124322,"accession_number":"0001477932-25-009240","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioNexus Gene Lab Corp. shareholders elect all four director nominees and approve 2025 equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors re-elected: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, Chee Keong Yap.","2025 Equity Incentive Plan approved with 966,759.8 votes for, 10,628.5 against.","JP Centurion & Partners PLT ratified as independent auditor for FY 2025.","Adjournment proposal approved if needed to solicit additional proxies.","All proposals passed; meeting held December 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124321,"accession_number":"0001477932-25-009186","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Chemrex subsidiary governance shake-up: four directors resign; new chairman appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Chemrex officers/directors (Too Kam Tham, Liong Tai Tan, Wei Foong Lim, Kuan Yew Tan) resigned on Dec 19, 2025.","Matthew L. Barsing appointed as chairman of Chemrex board; brings tech and public-sector experience.","Chemrex governance review ongoing, assessing historical compliance, governance, and operational matters.","Chemrex exploring potential CDMO expansion as part of strategic shift toward biotech development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124320,"accession_number":"0001477932-25-008724","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab secures $500M equity facility from ARC and exclusive VitaGuard MRD license in SE Asia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.","BGLC obtains exclusive, perpetual, royalty-free license for VitaGuard MRD liquid biopsy platform in Southeast Asia; $2M fee over 24 months, $500K minimum reagent purchases.","As part of strategic alliance, BGLC issued 392,329 shares to Fidelion (now 16.6% owner) and received 180 Fidelion shares (15% stake).","$500M facility complements $20M ATM program; BGLC retains discretion on draws. ARC prohibited from short-selling or hedging."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124319,"accession_number":"0001477932-25-008137","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioNexus files $100M shelf, enters $20M ATM with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.","Filed S-3 shelf registration registering up to $100M of securities, not yet effective.","Proceeds to support growth initiatives: term sheets with Fidelion Diagnostics (VitaGuard MRD) and BirchBioMed Inc.","Company focuses on precision diagnostics, gene-based technologies in Asia and U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124318,"accession_number":"0001477932-25-008044","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.","CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.","VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.","Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.","Conditions include IP license agreement; other definitive agreements not yet executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124317,"accession_number":"0001477932-25-007708","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.","BGLC will receive 1.5 million common shares of BirchBioMed in exchange.","Collaboration to commercialize FS2 (kynurenic acid) topical cream in Malaysia and Singapore.","Term sheet non-binding except 60-day exclusivity; no assurance definitive agreement will be reached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140992,"accession_number":"0001477932-25-005322","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.","VitaGuard is tumour-naïve ctDNA test with 0.02% VAF sensitivity, 95% cfDNA recovery; cost <$300 vs >$3,000 legacy assays.","Southeast Asia cancer incidence projected at 2.4M new cases annually by 2030, creating multi-billion-dollar recurring market.","Cross-shareholdings and license fee align both companies; rollout begins in Singapore and Malaysia.","Partnership includes joint development of companion diagnostics and AI-powered Cancer Interception System."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158764,"accession_number":"0001477932-25-004754","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Chong Set Fui (Angeline) as CFO and Principal Financial Officer, effective June 17, 2025.","Chong has 25+ years senior financial experience, most recently CFO of Avillion Berhad (2013-2024).","Monthly salary RM15,000 (~$3,500 USD) plus medical, fuel allowance, and discretionary bonus.","Appointment is for a fixed term from June 17, 2025 to June 16, 2027, renewable with one-month notice.","Su-Leng Tan Lee ceased as acting CFO concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158763,"accession_number":"0001477932-25-003114","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab regains Nasdaq minimum bid price compliance, avoids delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Panel confirmation on Apr 30, 2025, that BGLC met $1.00 minimum bid price rule.","Stock closed at $1.00+ for required consecutive business days as of Apr 23, 2025.","Company plans to expand RNA diagnostics and specialty chemicals via Chemrex and MRNA Scientific.","Appointed new independent board members and formed internal audit function to strengthen governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158762,"accession_number":"0001477932-25-002574","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"BioNexus Gene Lab Corp. effects 1-for-10 reverse stock split effective April 7, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-10 reverse split effective 12:01 a.m. ET April 7, 2025; shares reduced from 17,967,663 to 1,796,597.","No fractional shares issued; cash payment based on 10-day VWAP prior to effective date (corrects prior cash payment price).","Reverse split aims to regain compliance with Nasdaq Minimum Bid Price Rule by May 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158761,"accession_number":"0001477932-25-002406","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"BioNexus Gene Lab announces 1-for-10 reverse stock split effective April 7, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio; effective 12:01 a.m. ET on April 7, 2025.","Company aims to cure Nasdaq bid price deficiency; must close above $1.00 for 10 consecutive days by May 1, 2025.","No fractional shares issued; shareholders receive cash in lieu based on April 4, 2025 closing price.","New CUSIP number 090628306; ticker symbol BGLC unchanged.","Shareholders holding electronically or in brokerage accounts adjusted automatically; physical certificate holders to receive instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177168,"accession_number":"0001477932-25-001958","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioNexus Gene Lab shareholders approve reverse stock split at 1:5 to 1:10 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["98.36% of votes cast (4.94B) approved reverse stock split; ratio range of 1:5 to 1:10 at Board discretion.","Series Z Preferred Stock with 5B votes mirrored common stock votes exclusively for this proposal.","Adjournment proposal also passed with 98.60% approval.","Special Meeting held March 19, 2025; no other matters voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177167,"accession_number":"0001477932-25-001531","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BGLC partners with ML Tech to optimize Ethereum treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with ML Tech, an NFA-regulated AI wealth management platform, to optimize BGLC's Ethereum holdings.","ML Tech will provide institutional-grade trading strategies with advanced quantitative models and non-custodial execution.","Partnership follows BGLC's Ethereum treasury strategy to grow reserves while maintaining liquidity, transparency, and control.","CEOs of both companies expressed commitment to digital asset innovation and enhancing shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177166,"accession_number":"0001477932-25-001484","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab board approves Ethereum-focused treasury strategy, first Nasdaq-listed company to do so","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Ethereum (ETH) as the primary treasury asset; BGLC is first Nasdaq-listed company to do so.","Cites Ethereum's institutional credibility, staking yield, stablecoin dominance, and upcoming Pectra upgrade.","Released Ethereum Strategy Whitepaper publicly on company website.","Company incorporated in Wyoming, which has pro-blockchain regulations; Wyoming Stable Token Act cited.","CEO Sam Tan says Ethereum treasury strategy enhances financial resilience and attracts forward-thinking investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177165,"accession_number":"0001477932-25-001063","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["3.02","5.03","3.03","9.01"],"status":"ready","headline":"BioNexus Gene Lab creates Series Z Preferred with 5B votes to facilitate Reverse Stock Split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Created one share of Series Z Preferred Stock with 5,000,000,000 votes, solely on Reverse Stock Split matter.","Issued to director Muhammad Azrul bin Abdul Hamid on Feb 10, 2025, exempt under Section 4(a)(2).","Series Z will vote proportionally to common shares, increasing total votes but not affecting percentage for/against.","Purpose is to ensure passage of Reverse Stock Split at upcoming Special Meeting.","Share may be cancelled by Board or automatically upon shareholder approval of Reverse Split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177164,"accession_number":"0001477932-25-000006","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.","Company intends to effect a reverse stock split by April 7, 2025 if needed.","Effective Jan 30, 2025, Nasdaq requires 10-day prior notice of reverse split details, including shareholder approval date.","Failure to comply by May 1, 2025 will result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193946,"accession_number":"0001477932-24-006996","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"BioNexus Gene Lab receives Nasdaq delisting notice; appeals with compliance plan including reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.","Filed appeal on Nov 8, 2024; hearing stays trading suspension pending Panel decision.","Intends to present compliance plan including potential reverse stock split to regain listing compliance.","Appointed Jook Yuen Low as independent director effective Nov 5, assigned to Audit and Nomination committees.","Re-appointed Su-Leng Tan Lee as Secretary and appointed as President; no compensation change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193945,"accession_number":"0001477932-24-006440","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two directors resign from BioNexus Gene Lab board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wei Foong Lim and Koon Wai Wong resigned as directors on October 9, 2024.","Wong also vacated his Audit Committee and Corporate Governance & Nominating Committee roles.","No disagreement with company operations, policies, or practices cited by either resigning director.","No replacement directors announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193944,"accession_number":"0001477932-24-006352","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).","Auditor JP Centurion & Partners reappointed with 10,720,634 votes for.","2024 Stock Incentive Plan not approved: 4,094,117 for, 6,382,176 against.","Reverse stock split (1:2 to 1:10) not approved: 4,371,573 for, 6,378,201 against.","Company alleges former officer/director directed unlawful proxy solicitation affecting Proposals 3&4; board authorized investigation, may pursue litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210272,"accession_number":"0001477932-24-005924","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab enters biogas sector in Malaysia via partnership with Protech Builders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MRNA Scientific (BGLC subsidiary) and Protech Builders signed a 3-year teaming agreement to develop biogas plants in Malaysia.","Initial joint contribution of up to RM1,000,000 (~USD 235,000) for feasibility studies and project development.","Projects will convert plantation wastewater into renewable energy; Protech holds G7 license for unlimited-scale construction.","Protech has over 300 completed projects across Malaysia, including biogas and power transmission systems."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210271,"accession_number":"0001477932-24-005817","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab subsidiary signs outsourcing deal with Vitarray for mRNA detection in SE Asia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement for mRNA dynamic gene detection services targeting Southeast Asian market.","Vitarray, authorized by China's Huaxia Jingdu Renhe, supplies samples; MRNA Scientific handles testing.","MRNA Scientific expects testing cost reduction >25%, boosting profitability.","Initial batch of experimental tests to be conducted before long-term collaboration.","Aims to enhance early disease detection for cancer and cardiovascular conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210270,"accession_number":"0001477932-24-005680","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab invests $450K in color paste production; signs MOU with Shenzhen Rongguang Health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chemrex invests RM 2M (~$450K) to produce fine-quality color paste for composite industrial customers; operations start Sept 2024.","In-house production expected to increase profit margins, improve quality control, and enable competitive pricing.","Company plans additional production facilities in the Middle East and Vietnam; bulk purchasing synergies.","MOU with Shenzhen Rongguang Health Group aims to expand cancer screening, precision medicine, and preventative healthcare in Asia.","MRNA Scientific subsidiary will lead cancer screening expansion with advanced genomic testing across Southeast Asia and China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210269,"accession_number":"0001477932-24-005537","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioNexus Gene Lab reduces stockholder meeting quorum to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws on September 4, 2024, effective immediately.","Quorum for stockholder meetings lowered from majority to one-third of outstanding voting shares.","Amendment aligns with other governance provisions; no other bylaw changes disclosed.","Amended and Restated Bylaws filed as Exhibit 3.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210268,"accession_number":"0001477932-24-005339","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab (BGLC) announces MyCIF co-investment in AISB, total round RM 1.7M (~$390k)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Malaysian Securities Commission co-invests alongside BGLC in Ascension Innovation under ESI scheme; total round RM 1.7M (~USD 390k).","BGLC previously invested RM 1M; AISB is first recipient of MyCIF ESI scheme.","Proceeds to advance AI-driven healthcare platform aiCMS and support Malaysia's National EMR Plan 'One Patient, One Record'.","CEO Sam Tan cites confidence from government investment in AISB's technology and BGLC's strategic direction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210267,"accession_number":"0001477932-24-005269","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab invests RM 1M for equity stake in Ascension Innovation Sdn Bhd","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investment of RM 1 million (~USD 228k) for a significant equity stake in Ascension Innovation Sdn Bhd (AISB).","AISB operates the aiCMS platform integrating predictive analytics and AI tools for healthcare.","Investment executed through wholly-owned subsidiary MRNA Scientific Sdn Bhd on August 23, 2024.","Collaboration aims to integrate BGLC's genomic screening services with AISB's digital health platforms.","Strategic move to expand BGLC's presence in the digital health sector and enhance personalized care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210266,"accession_number":"0001477932-24-004096","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K/A","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioNexus Gene Lab Corp amends CEO/acting CFO compensation: base salary $35k/month effective July 1, 2024, plus back pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary for CEO/acting CFO Su-Leng Tan Lee set at $35,000 per month effective July 1, 2024.","Company will recognize back pay at this rate from when Tan Lee began serving as CEO and CFO.","Inducement Award Entitlement to be finalized by Compensation Committee in Q3 2024.","Amendment approved by Compensation Committee on June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228569,"accession_number":"0001477932-24-002622","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq grants BioNexus Gene Lab 180-day extension to meet $1 bid price rule through Nov 4, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Initial bid price deficiency notice received Nov 6, 2023; original 180-day cure period expired May 6, 2024.","On May 8, 2024, Nasdaq granted additional 180-day extension to regain compliance, now due by Nov 4, 2024.","To cure, closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.","If not cured, Nasdaq will delist; company may request hearing before Nasdaq Hearings Panel to stay delisting.","Company states it will use reasonable efforts but cannot assure it will regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228568,"accession_number":"0001477932-24-002229","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BioNexus Gene Lab invests RM1.2M for 10% stake in Malaysian digital health firm AISB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investment of RM1.2M (~$250k) via subsidiary MRNA Scientific for ~10% equity in Ascension Innovation (AISB).","Funding to accelerate AISB's AI platform aiCMS with predictive analytics, AI diagnosis aids, and more.","AISB projects revenue of RM75M collectively for 2024-2028; currently 145k+ users and 30+ providers.","Investment supports BGLC's genomic diagnostics integration into AISB's platform to expand market reach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228567,"accession_number":"0001477932-24-001695","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioNexus Gene Lab removes eight directors, appoints four new directors and new CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders owning 50.1% (17,792,663 shares) approved removal of eight directors and appointment of four new directors via written consent.","Eight prior directors removed: Yeat Min Fong, Chi Yuen Leong, Yee Meng Wong, Teng Fook Fong, Chee Keong Yap, Chak Hua Yew, Boon Teong Teoh, and Chai Ping Lin.","New directors: Koon Wai Wong, Wei Foong Lim, Muhammad Azrul bin Abdul Hamid, and Chee Keong Yap (independent); terms expire at 2024 annual meeting.","Su-Leng Tan Lee appointed CEO and Secretary effective Dec 11, 2023; two-year employment agreement with non-compete for 24 months after termination.","Board committees reconstituted: Audit (Chair: Chee Keong Yap), Compensation (Chair: Muhammad Azrul bin Abdul Hamid), Nomination & Corp Gov (Chair: Muhammad Azrul bin Abdul Hamid)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264662,"accession_number":"0001477932-23-008275","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioNexus Gene Lab receives Nasdaq bid-price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).","180-day compliance period ends May 6, 2024; cure requires $1.00 close for 10 straight days.","Company may be eligible for an additional 180-day cure period if it meets other listing standards.","Failure to cure could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264661,"accession_number":"0001477932-23-008068","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioNexus Gene Lab CFO Wei Li Leong resigns effective Oct 30, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wei Li Leong resigned as CFO effective October 30, 2023; will stay for one additional month.","Resignation not due to any disagreement with the company, management, or board.","Company to actively identify a replacement CFO; no successor named as of Nov 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264658,"accession_number":"0001477932-23-007962","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K/A","filed_at":"2023-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioNexus Gene Lab amends 8-K to disclose CEO and CFO are father and daughter","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Chi Yuen Leong's daughter, Wei Li Leong, serves as CFO.","Disclosure corrects omission in original October 2023 8-K.","No other changes to the original report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264660,"accession_number":"0001477932-23-007651","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bionexus Gene Lab appoints Chi Yuen Leong as CEO and director, effective Oct 12, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chi Yuen Leong appointed CEO and director effective October 12, 2023; annual compensation $24,000.","Leong previously served as President and director from company inception to August 2022.","He has no family relationships or reportable transactions with the company.","Leong brings experience from CEO role at US Arem Pacific Corp (2009-2015) and background in biotechnology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264659,"accession_number":"0001477932-23-007555","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bionexus Gene Lab CEO Sook Keng Yeoh resigns effective Oct 4; no successor named yet","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Sook Keng Yeoh resigned as CEO and director on October 4, 2023.","Resignation was not due to any disagreement with the Company, management, or Board.","Company currently has no CEO and is actively seeking a replacement.","President Yee Meng Wong remains; no interim CEO appointed at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281892,"accession_number":"0001477932-23-006695","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bionexus Gene Lab COO Liong Tai Tan resigns; Lee Su-Leng Tan appointed COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Liong Tai Tan resigned as COO and director effective August 31, 2023; no disagreement with company.","Board approved Lee Su-Leng Tan as COO effective September 1, 2023; he is not a director.","Lee Su-Leng Tan, aged 40, has over 20 years of experience in life sciences, hospitality, and property.","New COO entered employment agreement dated August 15, 2023, with annual compensation of $24,000.","Tan previously served as Chief Commercial Officer at Dryox Health and Managing Director at Biotechnology Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281891,"accession_number":"0001477932-23-005506","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["1.01","5.03","8.01","9.01"],"status":"ready","headline":"BioNexus closes $5.75M public offering and uplists to Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 1,437,500 shares at $4.00/share; gross proceeds $5.75M.","Underwriter fully exercised over-allotment option for 187,500 additional shares.","Common stock began trading on Nasdaq Capital Market on July 20, 2023 under symbol BGLC.","Underwriter issued warrants for 115,000 shares at $4.40/share, exercisable for 5 years.","Lock-up agreements with officers, directors, and certain shareholders for 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281890,"accession_number":"0001477932-23-005435","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"BioNexus Gene Lab Corp. completes 1-for-12 reverse stock split effective July 20, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-12 ratio effective July 20, 2023; prior 1-for-10 plan amended.","No fractional shares; odd lots under 100 shares rounded up to nearest whole share or 100 shares.","Authorized shares unchanged at 300M common and 30M preferred; par value unchanged.","New CUSIP following split: 090628207.","Split approved by stockholders and board on May 8, 2023; FINRA announced July 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356297,"accession_number":"0001477932-22-006086","cik":1737523,"company_name":"BioNexus Gene Lab Corp","ticker":"BGLC","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bionexus Gene Lab replaces Chairman, CEO, and President in leadership reshuffle","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chairman Soo Kow Lai, CEO Chan Chong Wong, and President Chi Yuen Leong resigned effective Aug 12, 2022; no disagreement cited.","Yeat Min Fong appointed Chairman, Sook Keng Yeoh CEO, Yee Meng Wong President, effective Aug 9, 2022.","Each new officer receives $12,000 annual salary and 25,000 common shares under employment agreements.","Fong has 15+ years in medical industry; Yeoh 41 years in management; Wong biochem background with 10+ years research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5435813.910765766,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}